4.4 Article

In vitro anti-inflammatory effects of vitamin D supple-mentation may be blurred in hemodialysis patients

期刊

CLINICS
卷 76, 期 -, 页码 -

出版社

HOSPITAL CLINICAS, UNIV SAO PAULO
DOI: 10.6061/clinics/2021/e1821

关键词

Hemodialysis; Inflammation; Interleukin-1 beta; hs-CRP; Mineral metabolism; Secondary hyperparathyroidism; Vitamin D

资金

  1. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [456617/2014-0]
  2. Coordenac<comma>ao de Aperfeic<comma>oamento de Pessoal de Nivel Superior (CAPES)

向作者/读者索取更多资源

Vitamin D supplementation improves hypovitaminosis D in hemodialysis patients but its effects on secondary hyperparathyroidism control are unclear. While exhibiting anti-inflammatory effects in vitro, short-term supplementation does not effectively improve the inflammatory profile of hemodialysis patients.
OBJECTIVES: This study aimed to evaluate the potential anti-inflammatory effects of vitamin D supplementation under uremic conditions, both in vivo and in vitro, and its effects on the parameters of mineral metabolism. METHODS: Thirty-two hemodialysis patients were randomly assigned to receive placebo (N=14) or cholecalciferol (N=18) for six months. Serum levels of calcium, phosphate, total alkaline phosphatase, intact parathyroid hormone (iPTH), and vitamin D were measured at baseline and after three and six months. The levels of fibroblast growth factor-23 (FGF-23), interleukin-1 beta (IL-1 beta), and high-sensitivity C-reactive protein (hs-CRP) were also measured at baseline and at six months. Human monocytes were used for in vitro experiments and treated with cholecalciferol (150 nM) and uremic serum. Cell viability, reactive oxygen species (ROS) production, and cathelicidin (CAMP) expression were evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, dichlorodihydro-fluorescein diacetate assay, and real time-quantitative polymerase chain reaction, respectively. RESULTS: Both patient groups were clinically and biochemically similar at baseline. After six months, the levels of vitamin D and iPTH were higher and lower, respectively, in the cholecalciferol group than in the placebo group (p <0.05). There was no significant difference between the parameters of mineral metabolism, such as IL-1 beta and hs-CRP levels, in both groups. Treatment with uremic serum lowered the monocyte viability (p<0.0001) and increased ROS production (p<0.01) and CAMP expression (p<0.05); these effects were counterbalanced by cholecalciferol treatment (p<0.05). CONCLUSIONS: Thus, cholecalciferol supplementation is an efficient strategy to ameliorate hypovitaminosis Din hemodialysis patients, but its beneficial effects on the control of secondary hyperparathyroidism are relatively unclear. Even though cholecalciferol exhibited anti-inflammatory effects in vitro, its short-term supplementation was not effective in improving the inflammatory profile of patients on hemodialysis, as indicated by the IL-1 beta and hs-CRP levels.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据